TScan Therapeutics (TCRX) Stock Price, News & Analysis

Company Overview

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell therapies for patients with cancer. The company’s approach is designed to harness the ability of T cells to recognize cancer-associated antigens presented on the surface of tumor cells, including targets that may be difficult to address with other forms of cell therapy.

TScan’s pipeline includes TCR-engineered therapies for both hematologic malignancies and solid tumors. Its TSC-100 and TSC-101 programs are being developed for patients undergoing allogeneic hematopoietic stem cell transplantation, with the goal of targeting minor histocompatibility antigens and reducing the risk of disease relapse. The company is also advancing a portfolio of TCR-T product candidates directed at tumor-associated antigens in solid tumors.

Founded in 2018 and headquartered in Waltham, Massachusetts, TScan conducts its research and clinical development activities primarily in the United States. The company is led by President and Chief Executive Officer David Southwell and is listed on the Nasdaq under the symbol TCRX.

Key Stats

• Today's Range: $0.20 to $0.23
• 50-Day Range: $0.21 to $0.82
• 52-Week Range: $0.20 to $2.57
• Volume: 546,577 shs
• Average Volume: 728,918 shs
• Market Capitalization: $14.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.67
• Consensus Rating: Hold

TScan Therapeutics Stock Analysis - MarketRank™

TScan Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 171st out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

TScan Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 2 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

TScan Therapeutics has a consensus price target of $2.67, representing about 1,166.2% upside from its current price of $0.21.

Amount of Analyst Coverage

TScan Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for TScan Therapeutics are expected to grow in the coming year, from ($0.79) to ($0.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TScan Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TScan Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TScan Therapeutics has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.91% of the float of TScan Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TScan Therapeutics has a short interest ratio ("days to cover") of 3.25, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TScan Therapeutics has recently increased by 9.04%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TScan Therapeutics does not currently pay a dividend.

Dividend Growth

TScan Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.82

News Sentiment

TScan Therapeutics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for TScan Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for TCRX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added TScan Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TScan Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.25% of the stock of TScan Therapeutics is held by insiders.

Percentage Held by Institutions

82.83% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TCRX
• CIK: 1783328
• Web: www.tscan.com
• Phone: 857-399-9500
• Fax: N/A
• Employees: 142
• Year Founded: 2018

Price Target and Rating

• Average Price Target for TScan Therapeutics: $2.67
• High Price Target: $6.00
• Low Price Target: $1.00
• Potential Upside/Downside: +1,166.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$129.77 million
• Net Margins: -1,655.35%
• Pretax Margin: -1,655.35%
• Return on Equity: -108.72%
• Return on Assets: -54.47%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 3.37
• Quick Ratio: 3.37

Sales & Book Value

• Annual Sales: $10.32 million
• Price / Sales: 1.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.16 per share
• Price / Book: 0.10

Miscellaneous

• Outstanding Shares: 67,780,000
• Free Float: 63,543,000
• Market Cap: $14.27 million
• Optionable: Not Optionable
• Beta: 1.15